RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

Company Overview

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Key Stats

• Today's Range: $1.26 to $1.33
• 50-Day Range: $0.36 to $0.50
• 52-Week Range: $0.31 to $7.70
• Volume: 74,053 shs
• Average Volume: 1.73 million shs
• Market Capitalization: $5.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RXII Stock Analysis - Frequently Asked Questions

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to the consensus estimate of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

When did RXi Pharmaceuticals' stock split?

RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of RXi Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Endologix (ELGX), Auris Medical (EARS), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 8/14/2018
• Today: 3/12/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RXII
• CIK: 1533040
• Web: www.rxipharma.com
• Phone: (508) 767-3861
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,450,000.00
• Net Margins: -4,990.20%
• Pretax Margin: N/A
• Return on Equity: -412.15%
• Return on Assets: -179.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 569.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.77 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 4,380,000
• Free Float: N/A
• Market Cap: $5.69 million
• Optionable: Not Optionable
• Beta: 2.07